Rezolute (RZLT) Return on Capital Employed (2013 - 2026)
Rezolute's (RZLT) quarterly Return on Capital Employed came in at 70.17% in Q1 2026, up 1292.0% year-on-year from 5.04% in Q1 2025, and down 8.6% quarter-over-quarter from 64.62% in Q4 2025.
Rezolute (RZLT) Return on Capital Employed (2013 - 2026) Analysis & Trends
Rezolute has disclosed Return on Capital Employed across 14 years of filings, most recently posting 70.17% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 70.17%, up 1292.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 70.17% (up 1292.0% YoY), and the FY2025 annual result was 56.18%, up 318.0% from the prior year.
- Return on Capital Employed came in at 70.17% for Q1 2026 at Rezolute, down from 64.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.27% in Q3 2022 to a low of 83.09% in Q1 2025.
- The 5-year median for Return on Capital Employed is 59.5% (2024), against an average of 56.21%.
- Across the five-year window, Return on Capital Employed soared 4139 bps in 2022 and sank 3147 bps in 2024, its largest moves.
- Rezolute's Return on Capital Employed stood at 31.79% in 2022, then plunged by 97 bps to 62.76% in 2023, then retreated by 9 bps to 68.47% in 2024, then increased by 6 bps to 64.62% in 2025, then decreased by 9 bps to 70.17% in 2026.
- The last three Return on Capital Employed figures came in at 70.17% (Q1 2026), 64.62% (Q4 2025), and 52.76% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Rezolute | 520.13 Mn | 520.13 Mn | - | -70.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.17% |
| Dec 31, 2025 | -64.62% |
| Sep 30, 2025 | -52.76% |
| Jun 30, 2025 | -64.85% |
| Mar 31, 2025 | -83.09% |
| Dec 31, 2024 | -68.47% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -69.98% |
| Mar 31, 2024 | -69.96% |
| Dec 31, 2023 | -62.76% |
| Sep 30, 2023 | -55.49% |
| Jun 30, 2023 | -45.24% |
| Mar 31, 2023 | -38.50% |
| Dec 31, 2022 | -31.79% |
| Sep 30, 2022 | -29.27% |
| Jun 30, 2022 | -38.55% |
| Mar 31, 2022 | -50.52% |
| Dec 31, 2021 | -58.35% |
| Sep 30, 2021 | -70.66% |
| Jun 30, 2021 | -63.94% |